hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-04-12. Anything still debated is marked as such rather than presented as settled.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Dichloroacetic acid (DCA), sometimes called bichloroacetic acid (BCA), is the organic compound with formula CHCl2CO2H. It is an analogue of acetic acid, in which 2 of the 3 hydrogen atoms of the methyl group have been replaced by chlorine atoms. Like the other chloroacetic acids, it has various practical applications. The salts and esters of dichloroacetic acid are called dichloroacetates.
Legumin is a conjugated protein with six subunits. The individual subunits have a hydrophilic α chain that is initially linked to the smaller hydrophobic β chain with a peptide bond. Both the α and β chains are encoded by the same gene. Each of the six subunits has a mass of ~50-60 kDa. During translation of the α and β chains, the polypeptide is inserted into the endoplasmic reticulum (ER) where the signal peptide that initiated the cell to translocate the chains is cleaved. A disulfide bridge is formed between the α and β chains to form prolegumin, a protein precursor. Three of these subunits come together to form a trimer in the ER. The trimer of prolegumins can be transported to the vacuole for further post-translational modification. In the vacuole, the peptide bond formed between the α and β chains is cleaved now that the disulfide bridge holds the two chains together. The cleavage of the α and β chains within the trimers signals protein maturation where two trimers to come together and form the final hexameric legumin protein.
The West Gulf warehouse was built in 1984 in La Porte, TX. At 140,000 square feet (13,000 m2) and 4,200,000 cubic feet (120,000 m3), this facility can blast freeze up to 1,280,000 lbs of meat and poultry a day. There are 32 truck platforms and the warehouse is accessible to all Class 1 railroads serving the Houston area. It also maintains certifications for Russian poultry shipments as well as Russian export and Russian pork Trichinosis certifications. It is a USDA approved meat inspection establishment and has the ability to do Trichinae testing.
== Ease of doing business == World Bank's Doing Business 2017; Equal Opportunity for All: Thailand ranked 46th (1-easiest; 190=difficult) of 190 nations in the "Ease of Doing Business" rankings. Other ASEAN states ranked: Singapore, 2; Malaysia, 23; Brunei, 72; Vietnam, 82; Indonesia, 91; Philippines, 99; Cambodia, 131; Laos, 139; Myanmar, 170. World Bank's Doing Business 2016: Measuring Regulatory Quality and Efficiency: Thailand ranked 49th overall of 189 nations (1=best, 189=worst) in ease of doing business, a drop of three places in the rankings since the 2014 survey prior to the May coup. Among ASEAN nations, Thailand ranked third behind Singapore and Malaysia. In detailed rankings, Thailand ranked 97th worldwide in getting credit, 96th in ease of starting a business, 70th in paying taxes, 39th in dealing with construction permits, 57th in registering property and enforcing contracts, 56th in trading across borders, 36th for protecting minority investors, and 49th in resolving insolvency.
== Ethical, legal and social implications == Genetic information provides a unique type of knowledge about an individual and his/her family, fundamentally different from a typically laboratory test that provides a "snapshot" of an individual's health status. The unique status of genetic information and inherited disease has a number of ramifications with regard to ethical, legal, and societal concerns. On 19 March 2015, scientists urged a worldwide ban on clinical use of methods, particularly the use of CRISPR and zinc finger, to edit the human genome in a way that can be inherited. In April 2015 and April 2016, Chinese researchers reported results of basic research to edit the DNA of non-viable human embryos using CRISPR. In February 2016, British scientists were given permission by regulators to genetically modify human embryos by using CRISPR and related techniques on condition that the embryos were destroyed within seven days. In June 2016 the Dutch government was reported to be planning to follow suit with similar regulations which would specify a 14-day limit.
Sources: en.wikipedia.org
=== Automation === In the past, oligonucleotide synthesis was carried out manually in solution or on solid phase. The solid phase synthesis was implemented using, as containers for the solid phase, miniature glass columns similar in their shape to low-pressure chromatography columns or syringes equipped with porous filters. Currently, solid-phase oligonucleotide synthesis is carried out automatically using computer-controlled instruments (oligonucleotide synthesizers) and is technically implemented in column, multi-well plate, and array formats. The column format is best suited for research and large scale applications where a high-throughput is not required. Multi-well plate format is designed specifically for high-throughput synthesis on small scale to satisfy the growing demand of industry and academia for synthetic oligonucleotides.
Prepared commercial blends may be sold as a powder or as a concentrated gelatinous block, divided into small squares. Either type is mixed with sufficient hot water to completely dissolve it, and then mixed with enough cold water to make the volume of liquid specified on the packet. The solubility of powdered gelatine can be enhanced by sprinkling it into the liquid several minutes before heating, "blooming" the individual granules. The fully dissolved mixture is then refrigerated, slowly forming a colloidal gel as it cools. Gelatine desserts may be enhanced in many ways, such as using decorative moulds, creating multicoloured layers by adding a new layer of slightly cooled liquid over the previously solidified one, or suspending non-soluble edible elements such as marshmallows or fruit. Some types of fresh fruit and their unprocessed juices are incompatible with gelatine desserts; see the Chemistry section below. When fully chilled, the most common ratios of gelatine to liquid (as instructed on commercial packaging) usually result in a custard-like texture which can retain detailed shapes when cold but melts back to a viscous liquid when warm. A recipe calling for the addition of additional gelatine to regular jelly gives a rubbery product that can be cut into shapes with cookie cutters and eaten with fingers (called "Knox Blox" by the Knox company, makers of unflavoured gelatine). Higher gelatine ratios can be used to increase the stability of the gel, culminating in gummy candies which remain rubbery solids at room temperature (see Bloom (test)).
While fluoxetine remains the only FDA-approved antidepressant for children as young as 8, modern clinical guidelines emphasize rigorous monitoring during the first 12 weeks of treatment—the period identified as having the highest risk for the onset of suicidal ideation.
Following the 2024 United States elections, in which the Republican Party retained the House of Representatives and won the Senate, Republicans began negotiations on passing then-president-elect Donald Trump's domestic policies. In a meeting with Senate Republicans in December 2024, Senate majority leader John Thune outlined an approach involving initial legislation on border security, energy production, and the military while reserving tax policy. Trump, in contrast, advocated for a singular bill to resolve an impending lapse in tax cuts implemented in the Tax Cuts and Jobs Act in 2017. However, this strategy faced risks from defecting members. In January 2025, Republicans met in Fort Lesley J. McNair. At the meeting, Speaker of the House Mike Johnson stated that Trump sought "one big, beautiful bill" to enact his policies. To more easily pass the bill, Republicans chose to use the budget reconciliation process, which allowed them to avoid the 60-vote Senate filibuster, which carried importance as they hold 53 seats out of 100 in the Senate. This requires the House and the Senate to pass identical instructions before passing the actual reconciliation bill. Before being signed into law, the Senate approved the bill 51–50 on July 1, 2025, with Vice President JD Vance casting a tiebreaking vote in support. It passed the House of Representatives, 218–214, on July 3, 2025. It passed over universal Democratic opposition in both houses.
As the Pizarro approached the Canary Islands, it passed Lanzarote on 16 June 1799, where Humboldt and Bonpland observed volcanic landscapes, including the Timanfaya volcano, which had last erupted in the 1730s. Navigation among the islands was challenging due to fog and unpredictable winds. The crew mistook a rock formation on Graciosa for a coastal castle, and the ship narrowly avoided being driven onto rocks by strong currents during the night. On 19 June 1799, the Pizarro arrived near Grand Canary. Dense fog delayed progress, but as it cleared, the ship’s company saw Pico del Teide, the volcanic peak of Tenerife, which Humboldt and Bonpland intended to ascend. British warships were observed nearby, but the Pizarro was protected by the guns of a Spanish fort and continued safely.
Sources: en.wikipedia.org
=== Heart disease === Macrophages are the predominant cells involved in creating the progressive plaque lesions of atherosclerosis. Focal recruitment of macrophages occurs after the onset of acute myocardial infarction. These macrophages function to remove debris, apoptotic cells and to prepare for tissue regeneration.
=== Cellular transport === Along with sodium and the vitamins biotin (B7) and pantothenic acid (B5), lipoic acid enters cells through the SMVT (sodium-dependent multivitamin transporter). Each of the compounds transported by the SMVT is competitive with the others. For example research has shown that increasing intake of lipoic acid or pantothenic acid reduces the uptake of biotin and/or the activities of biotin-dependent enzymes.
=== Grand Lodge of South Carolina === On March 27, 1818, the Grand Lodge of South Carolina chartered La Constancia Lodge, No. 50. On March 31, 1820, they chartered La Amenidad Lodge, No. 52. Both of these were chartered in Havana. In 1821, the Grand Lodge of Ancient Freemasons sent a communication to the Grand Lodge of South Carolina that a new Grand Lodge had been formed in Cuba, and La Amenidad Lodge, No. 52 had expressed its desire to transfer to the new Grand Lodge. The Grand Lodge of South Carolina accepted the arrangement. However, La Constancia Lodge, No. 50, remained a part of the Grand Lodge of South Carolina until its members surrendered its warrant around the year 1824, stating that their decision was made "in consequence of the religious and political persecutions to which they were subjected."
== Mechanism of action == The primary mechanism of action by PDRN is the adenosine A2A receptor pathway, which is activated following enzymatic degradation of the deoxyribonucleotide polymers. Adenosine acts the primary ligand which binds to the G protein-coupled receptor A2A leading to an increase in intracellular cyclic AMP (cAMP) levels. This secondary messenger activates protein kinase A (PKA) acting as a signaling cascade of several pathways downstream.Thus, enhacing tissue repair through upregulation of PI3K/Akt and vascular endothelial growth factor (VEGF). The activation of the A2A pathway is observed to be conserved across various PDRN sources, yet it activates different downstream pathways depending on the type of tissue and injury. Additionally, PDRN contributes to the salvage pathway, which is a metabolic mechanism that supports nucleotide synthesis for processes like DNA replication and celullar proliferation. For injuries needing faster regeneration, this nucleoside input is essential, highlighling the importance of both signaling and metabolic pathways for optimal tissue repair.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.